Literature DB >> 17262987

Intrinsically disordered tau protein in Alzheimer's tangles: a coincidence or a rule?

R Skrabana1, M Skrabanova, N Csokova, J Sevcik, M Novak.   

Abstract

Tau protein, the major constituent of neurofibrillary tangles in Alzheimer's disease (AD) and related tauopathies, is classified as intrinsically disordered protein (IDP). IDPs in contrast to globular proteins contain high proportion of polar and charged amino acids in their sequence, which results in the absence of a well-defined three-dimensional structure of the free protein. Structural flexibility of IDPs is required to perform their important role in many cellular processes. In the course of tauopathies, highly soluble disordered tau protein acquires rigid fold and forms highly insoluble filaments. Beneficial intrinsic disorder transforms into a fatal order: is it a coincidence, or is there an underlying reason for preferential IDPs assembly? In this review we present the structural characteristics of tau protein filamentous lesions in AD and discuss the tendency of IDPs to assembly and to form amyloid deposits (Ref: 65).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17262987

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  3 in total

Review 1.  Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy.

Authors:  Eva Kontsekova; Natalia Ivanovova; Martina Handzusova; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-02-13       Impact factor: 5.046

2.  Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragments.

Authors:  Ondrej Cehlar; Rostislav Skrabana; Andrej Kovac; Branislav Kovacech; Michal Novak
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-09-25

Review 3.  Tau-mediated synaptic damage in Alzheimer's disease.

Authors:  Santosh Jadhav; Veronika Cubinkova; Ivana Zimova; Veronika Brezovakova; Aladar Madari; Viera Cigankova; Norbert Zilka
Journal:  Transl Neurosci       Date:  2015-10-23       Impact factor: 1.757

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.